Loading TMDX detail
Loading ticker data...
Loading TMDX detail
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Chart data unavailable
SG Americas Securities LLC grew its position in TransMedics Group, Inc. (NASDAQ: TMDX) by 125.8% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,725 shares of the company's stock after buying an additional 8,762 shares during the quarter. SG Americas Securities
TransMedics Group (NASDAQ: TMDX - Get Free Report) and WORK Medical Technology Group (NASDAQ: WOK - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations and earnings. Earnings and Valuation This table compares
TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock?
TMDX rides OCS adoption and strong fourth-quarter results, but margin pressure raises questions for investors.
Disaboom (OTCMKTS:MEDH - Get Free Report) and TransMedics Group (NASDAQ: TMDX - Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, valuation, risk and dividends. Profitability This table compares Disaboom and TransMedics Group's net
TransMedics Group (NASDAQ: TMDX) CEO Waleed Hassanein and CFO Gerardo Hernandez-Omana provided updates on the company's strategy, clinical trial planning, and operational initiatives during a fireside chat hosted by Oppenheimer senior medical devices analyst Suraj Kalia. Expanding TransMedics' role in the U.S. transplant ecosystem Hassanein said TransMedics began as a medical device company and emphasized the
TransMedics is positioned for accelerating growth, with revenue expected to expand around 25% in 2026 and free cash flow breakeven by late 2026 or early 2027. TMDX is over the crest of its capex cycle, with investment pressures expected to ease, supporting margin expansion toward a 30% target by 2028. Despite a weak balance sheet and potential for 15% shareholder dilution in 2026, I remain bullish as long as revenue growth stays above 20% y/y.
ArrowMark Colorado Holdings LLC boosted its stake in shares of TransMedics Group, Inc. (NASDAQ: TMDX) by 54.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 313,125 shares of the company's stock after purchasing an additional 109,830 shares during the quarter. ArrowMark
TransMedics has transitioned into a fundamentally strong, profitable growth story with reduced volatility and clear operational leverage. TMDX delivered a robust Q4, exceeding revenue and earnings estimates, with 32% Y/Y growth and expanding operating margins by over 610 bps. Management guides for 20-25% revenue growth in 2026, with Liver segment dominance and significant upside potential from Heart, Lung, and Kidney programs.
Five of the Fund's 10 equity sectors made a positive impact on calendar year performance, led by Industrials, Financials, and Information Technology. Alamos Gold's positive earnings outlook, a renewed stock buyback program, and rising gold prices all helped its stock to climb throughout 2025. Management reported a 48% increase in total revenue for 1Q25 compared to 1Q24, driven by OCS liver and heart transplants.
TransMedics remains the top dog in its industry and may have a widening moat. The founder-led company's shares have risen eightfold since 2019.
These four tickers aren't hype stocks; they're the plumbing in solid industries. Axon Enterprise has switching costs; Vertiv is embedded in AI infrastructure; TransMedics controls a life-critical logistics network; and Fair Isaac has regulatory entrenchment and pricing power.
Medical stock TransMedics is in a cup-with-handle base with a buy point of 151.85.
TransMedics is helping improve organ transplantation thanks to its innovative organ storage system. The company has posted strong financial results over the past few years, and the stock is soaring.
ANDOVER, Mass., Feb. 27, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today issued additional information on the impact of the valuation allowance on deferred tax assets reported in the Company's fourth quarter financial results for the year ended December 31, 2025.
